Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Similar documents
Monitoring Hepatitis C

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

Liver 102: Injury and Healing

Hepatology For The Nonhepatologist

Non-Invasive Testing for Liver Fibrosis

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Medical Policy Non-invasive Tests for Hepatic Fibrosis

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

New York State HCV Provider Webinar Series. Overview of Fibrosis Staging, Child s Pugh, MELD Scores

New York State HCV Provider Webinar Series

Module 1 Introduction of hepatitis

New York State HCV Provider Webinar Series. Overview of Fibrosis-Staging, Child s Pugh, MELD Scores

Approach to the Patient with Liver Disease

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

INHSU th International Symposium on Hepatitis Care In Substance Users

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Pretreatment Evaluation

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Patterns of abnormal LFTs and their differential diagnosis

Non-invasive diagnosis of hepatitis B virus-related cirrhosis

Pretreatment Evaluation

NAFLD and NASH: The Not-So-New Kids on the Block

NON-ALCOHOLIC FATTY LIVER DISEASE:

Initial Evaluation for HCV Therapy. Hope McGratty PA-C, MPH

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Hepatology for the Nonhepatologist

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Pretreatment Evaluation

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Investigating and Referring Incidental Findings of Abnormal Liver Tests

AASLD Immune tolerant phase HBV NAFLD diagnostic HCC

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

Break the Liver Biopsy Habit

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Learning Objectives. After attending this presentation, participants will be able to:

Page: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease

Disclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease

Diagnosis and Management of PBC

Evaluating Obese Persons With Abnormal Liver Chemistries

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

Management of Liver Diseases: A Nonhepatologist s Viewpoint

The New World of HCV Therapy

Assessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia

The Future is Here Now!

EVALUATION OF ABNORMAL LIVER TESTS

Patterns of abnormal LFTs and their differential diagnosis

HEP DART 2017, Kona, Hawaii

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Imaging of liver and pancreas

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

Non-Alcoholic Fatty Liver Disease (NAFLD)

JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

Disclosure. Evaluation of Abnormal Hepatic Enzymes

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp

Clinical Policy Title: Liver elastography

Surveillance for Hepatocellular Carcinoma

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Section: Laboratory Last Reviewed Date: May Policy No: 47 Effective Date: August 1, 2014

A Rational Evidence-based Approach to Abnormal Liver Tests

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

Supplementary appendix

Liver Ultrasound - Beyond the Basics. Pamela Parker Lead Sonographer

3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab

Interpreting Liver Function Tests

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Transient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

5/2/2016. Arthur Y. Kim, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital Boston, Massachusetts

Evaluation and Staging of Liver Fibrosis

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

The authors have declared no conflicts of interest.

Transcription:

Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD

Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis Non-invasive means of liver fibrosis evaluation Summary

Liver Moore KL, Dalley AF. Clinically oriented anatomy, 4 th edition: Philadelphia: Lippincott Williams & Wilkins, 1999: 268

Liver-related Labs Aspartate Aminotransferase (AST) Alanine Aminotransferase (ALT) Alkaline Phosphatase Gamma Glutamyl Transpeptidase (GGT) Bilirubin Albumin Prothrombin time (PT/INR) Platelet count

Causes of Chronic Liver Disease Chronic Viral Hepatitis (B,C) Alcoholic Liver Disease Nonalcoholic Fatty Liver Disease Autoimmune Liver Diseases (Autoimmune Hepatitis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis) Inherited Metabolic Defects (Hemochromatosis, Wilson Disease, Alpha-1-antitrypsin deficiency, etc.) Other

Progression of Chronic Liver Disease Pellicoro A, Ramachandran P et al; Nature Reviews Immunology 14; 181-194 (2014)

Staging of Liver Fibrosis Faria S, Ganesan K, et al. MR imaging of liver fibrosis: current state of art; 2009; Oct; 29(6); 1615-35

Liver Biopsy Percutaneous Transjugular Laparoscopic EUS-guided http://www.mayoclinic.org/tests-procedures/liver-biopsy/multimedia/liver-biopsy/img-20007146

Liver Biopsy Benefits Risks Pitfalls: 1. Sampling error 2. Subjective bias 3. Impracticability in obtaining serial biopsies

Noninvasive Assessment of Liver Fibrosis Serologic tools: AST/ALT ratio AST to Platelet ratio index (APRI) FIB-4 Forns index FibroSure FibroScore FibroSpect FibroMeter ELF score Imaging tools: Traditional modalities (Ultrasound, CT, MRI) Newer techniques (Transient Elastography, Acoustic Radiation Force Impulse Imaging & Magnetic Resonance Elastography)

Wai CT, Greenson JK, et al. A simple noninvasive index can predict both cirrhosis and advanced fibrosis in chronic hepatitis C; Hepatology; 2003; Aug; 38(2):518-26 APRI Higher APRI score predictive of advanced fibrosis APRI<1 = no/mild fibrosis; APRI>2=cirrhosis

Serologic Tools for Fibrosis Assessment Higher APRI score predictive of advanced fibrosis APRI<1 = no/mild fibrosis; APRI>2=cirrhosis Vallet-Pichard A, et al. FIB-4: an inexpensive and accurate marker of fibrosis. Hepatology 2007; 46; 32-6 Koda M et al. Fibroindex, a practical index for predicting significant fibrosis in pts with chronic hep C. Hepatology; 2007; 45; 297-306

Cross-sectional Imaging Ultrasound: heterogeneous texture Babu SA, et al. Elastography in chronic liver disease. Radiographics 2016 CT: nodular liver contour

Cross-sectional Imaging CT: Caudate lobe hypertrophy MRI: Dilated portal vein Babu SA, Wells M, et al. Elastography in chronic liver disease: Modalities, techniques, limitations and future directions. Radiographics; 2016; 36; 1987-2006

Cross-sectional Imaging Pitfalls: Lack of objectivity Inability to diagnose lesser degrees of fibrosis Even cirrhosis can be missed when gross changes in liver are not evident on imaging Subtle signs of cirrhosis have low inter-reader agreement

Transient Elastography Results in KPa Range: 2.5-75 KPa Tapper EB, Afdhal NH. Noninvasive assessment of disease progression. Zakim & Boyer s Textbook of Hepatology; 6 th edition

Transient Elastography FS > 7.1 KPa advanced fibrosis FS > 12.5 KPa cirrhosis Castera L, Vergniol J, et al. Prospective comparison of transient elastography, Fibrotest, APRI & liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastro. 2005. Feb, 128 (2): 343-50

Transient Elastography Pitfalls: Failure to obtain a valid result (obesity, narrow intercostal spaces, etc.) Can be spuriously high during a hepatitis flare On the contrary, Transient Elastography can also help diagnose cirrhosis in patients under-staged by biopsy Gara N, Zhao X, et al. Discordance among transient elastography, APRI and histologic assessment of liver fibrosis in patients with chronic hepatitis C; CGH. 2013; 11(3); 303-8.

Magnetic Resonance Elastography (MRE) 3-dimensional imaging Potential to assess the stiffness of entire liver High technical success in obese & NASH patients as well Results range from 0.5 to 10 KPa Not available widely Expensive Requires trained radiologists

Magnetic Resonance Elastography (MRE) MRE: focal increased stiffness MRI T2W: corresponding confluent fibrosis Babu SA, Wells M, et al. Elastography in chronic liver disease: Modalities, techniques, limitations and future directions. Radiographics; 2016; 36; 1987-2006

Summary Chronic liver disease from varied causes can lead to liver fibrosis Liver biopsy is considered the gold standard for fibrosis assessment Noninvasive tools have been proven to be reliable in differentiating between advanced and non-advanced fibrosis APRI is a simple index based on routine lab tests that can accurately diagnose cirrhosis and advanced fibrosis Elastography of the liver provides objective estimates of liver fibrosis using either ultrasound or MR techniques